BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: Several promising strategies have also entered clinical trials, and some preliminary results showed that TKIs in combination with IFN-α, JAK2 inhibitors, PPAR-γ agonists, BCL-2 inhibitors, and lysosomotropic agents have the potential to improve treatment response in CML (169, 170).